Opinion · 22 Oct 2024
Conference abstractPublished 2018
Liposan-A drug for the treatment of hemorrhagic shock
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Massive blood loss accompanied by hemorrhagic shock is the leading cause of the high (15-30%) mortality of victims. There is currently no significant trend towards its decline. This is because the resuscitation measures currently available are mainly aimed at protecting the normal cells that remain undamaged by the shock effect. Moreover, the onset of resuscitation is accompanied by an increase in cellular damage. The damaged cells eventually become necrotic, resulting in the patient either dying or remaining disabled. The problem of restoring the functions of damaged cells still remains unresolved due to the lack of effective methods for correcting the cellular membrane structures. L i po san (“empty” phosphatidylcholine liposomes) is a drug whose action is aimed at restoring the structure and functions of damaged cells both in the early and late stages of hemorrhagic shock. The drug is an effective agent that acts at the subcellular, organ and systemic levels. L i posan restores the structures of the liver, brain, lung and spleen to a considerable extent. When administered during late-stage experimental hemorrhagic shock, Liposan induces an increase in systemic arterial blood pressure within 20-30 minutes on average to 70 mm Hg. This is followed by a stabilization of arterial blood pressure at the subnormal level during 4 hours of observation. Animals under such conditions have their life expectancy increased by an average of 7 hours. T h e ad vantage of liposan is its high efficiency in treating latestage hemorrhagic shock in cases where conventional treatment methods, including transfusion and infusion therapy, often prove ineffective. The dispensing of liposan at the local clinic will greatly help reduce mortality and disability resulting from massive blood loss and hemorrhagic shock due to its pronounced membranerestorative action.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in International Journal of Drug Development and Research.
Opinion · 22 Oct 2024
From Monoclonal Antibodies to CAR-T Therapy: Trends and Transformations in Cancer Treatment
Perspective · 21 Oct 2024
Natural Products in Drug Discovery: From Traditional Remedies to Modern Medicines
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Drug Development and Research
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Galina Feodorovna Leskova”
- BylineArticles whose byline prints “V I Shvets”
- BylineArticles whose byline prints “Yu M Krasnopolskii”
